ELI LILLY AND COMPANY Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
ELI LILLY AND COMPANY (LLY) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $63.10 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2025-02-19
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for the quarter ending 2013-09-30 was $630.00M.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for the quarter ending 2011-09-30 was $260.00M.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for the quarter ending 2011-03-31 was $200.00M.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $63.10M, a 61.79% increase from fiscal 2023.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $39.00M, a 257.80% increase from fiscal 2022.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $10.90M, a 34.57% increase from fiscal 2021.
- ELI LILLY AND COMPANY unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2021 was $8.10M, a 84.54% decline from fiscal 2020.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 3 month | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month as first filed |
|---|---|---|---|
| 2024-12-31 | $63.10M 10-K · filed 2025-02-19 | ||
| 2023-12-31 | $39.00M 10-K · filed 2025-02-19 | ||
| 2022-12-31 | $10.90M 10-K · filed 2025-02-19 | ||
| 2021-12-31 | $8.10M 10-K · filed 2024-02-21 | ||
| 2020-12-31 | $52.40M 10-K · filed 2023-02-22 | ||
| 2019-12-31 | $100.30M 10-K · filed 2022-02-23 | ||
| 2018-12-31 | $115.40M 10-K · filed 2021-02-17 | $117.10M 10-K · filed 2019-02-19 | |
| 2017-12-31 | $59.30M 10-K · filed 2020-02-19 | ||
| 2016-12-31 | $12.10M 8-K · filed 2019-10-24 | $15.20M 10-K · filed 2017-02-21 | |
| 2015-12-31 | $45.20M 10-K · filed 2018-02-20 | ||
| 2014-12-31 | $32.10M 10-K · filed 2017-02-21 | ||
| 2013-12-31 | $358.20M 10-K · filed 2016-02-19 | ||
| 2013-09-30 | $630.00M 10-Q · filed 2014-10-29 | ||
| 2012-12-31 | $38.50M 10-K · filed 2015-02-19 | ||
| 2011-12-31 | $492.30M 10-K · filed 2014-02-19 | -$492.30M 10-K · filed 2012-02-24 | |
| 2011-09-30 | $260.00M 10-Q · filed 2011-10-28 | ||
| 2011-03-31 | $200.00M 10-Q · filed 2011-10-28 | ||
| 2010-12-31 | $30.20M 10-K · filed 2013-02-21 | -$30.20M 10-K · filed 2011-02-22 | |
| 2009-12-31 | -$128.90M 10-K · filed 2012-02-24 | -$45.10M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |